Engineering a Next-Gen IL2 Therapy.

The "immunocytokine" PD1-IL2v, a fusion of a PD-1 antibody and modified IL2, may circumvent some side effects of the decades-old recombinant IL2 therapy aldesleukin while also enhancing efficacy. Whether this strategy works in patients is now being put to the test in a clinical trial.